Bionano Genomics Equity Warrants Exp 21 Sep 2023 *W EXP 09/21/2023
Change company Symbol lookup
Select an option...
BNGOW Bionano Genomics Equity Warrants Exp 21 Sep 2023 *W EXP 09/21/2023
CVR Chicago Rivet & Machine Co
T AT&T Inc
HOMB Home BancShares Inc
ALG Alamo Group Inc
MGNX MacroGenics Inc
PSEC Prospect Capital Corp
SPEC Spectralcast Inc
RC Ready Capital Corp

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

Closing Price
Day's Change
-0.0312 (-10.06%)
B/A Size
Day's High
Day's Low

10-day average volume:

Rivian's stock tumbles toward a record low on report of Ford's plan to sell, dragging Amazon down with it

9:27 am ET May 9, 2022 (MarketWatch)

Shares of Rivian Automotive Inc. (RIVN) tumbled 16.3% toward a record low in premarket trading Monday, after media reports that major shareholder Ford Motor Co. (F) is planning to a large chunk of its stake in the electric vehicle maker. CNBC reported over the weekend that Ford was selling 8 million shares of Rivian, as the lock-up agreement, which required pre-initial-public-offering investors to hold onto their Rivian stock for at least 180 days, was set to expire on Sunday. The stock was set to open at a price that was about 69% below the $78 IPO price, and 86.0% below the record close of $172.01 on Nov. 16, 2021. Ford's stock took a 2.7% hit ahead of the open. The selloff in Rivian's stock also appeared to weigh on the shares of Inc. (AMZN), which slumped 3.2% premarket toward a two-year low. Amazon disclosed recently that it held 158 million shares of Rivian, or 18% of the shares outstanding, as of March 31. Amazon had booked a $7.6 billion loss on its Rivian investment in the latest quarter.

-Tomi Kilgore


(END) Dow Jones Newswires

May 09, 2022 09:27 ET (13:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.